The Health After Cancer podcast brings together Stanford Medicine physicians, cancer survivors and advocates to discuss issues around cancer survivorship and health after cancer treatment.
Stanford Medicine brain cancer researchers joined other thought leaders in Washington, D.C. to discuss what the Biden Administration-led Cancer Moonshot initiative could mean.
Stanford Medicine researchers take a unique approach to refine engineered immune cells meant to kill cancer.
Neurosurgeon Michael Lim studies how to unleash the immune system to attack a type of brain cancer called glioblastoma.
A common ovarian cancer evades detection by convincing nearby immune cells to treat it as a developing fetus.
Stanford scientists have taken important steps toward figuring out how to use immune therapy for a group of severe pediatric brain tumors.
A team led by Howard Chang has contributed key technology to enable new experimental cancer therapy that uses CRISPR to edit immune cells.
Screening more than 9,000 pairs of drugs helped Stanford and NIH scientists identify two drugs that synergize against a deadly childhood brain tumor.
Pioneering immunotherapy drug Provenge is enjoying a revival, thanks to a large new clinical trial that will test it in men with early prostate cancer.
Scientists have modified immune cells, imbuing them with the ability to not only detect, but reveal, the presence of a tumor.
A small change in how patients learn to think about side effects of a food allergy treatment greatly reduces their anxiety, Stanford researchers found.
Stanford scientists have moved a big step closer toward using engineered immune cells to treat many forms of pediatric cancer.
Sharon Chinthrajah weighs in on a new peanut allergy immunotherapy, speaking to its potential and its role in the future of food allergies therapy.